PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma

Cell Death & Disease, Published online: 30 March 2024; doi:10.1038/s41419-024-06615-8PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma

Source: Cell death and disease - March 30, 2024 Category: Internal Medicine Authors: Jiaxin Cao Kangmei Zeng Qun Chen Ting Yang Feiteng Lu Chaozhuo Lin Jianhua Zhan Wenjuan Ma Ting Zhou Yan Huang Fan Luo Hongyun Zhao Source Type: research